Switch theme
Sign up to access all valuation multiples
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
2014
n/a
LTM Revenue $2.4M
LTM EBITDA -$4.0M
$35.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Proteomics International has a last 12-month revenue (LTM) of $2.4M and a last 12-month EBITDA of -$4.0M.
In the most recent fiscal year, Proteomics International achieved revenue of $0.6M and an EBITDA of -$5.4M.
Proteomics International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Proteomics International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Profit | $2.4M | XXX | $0.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$4.0M | XXX | -$5.4M | XXX | XXX | XXX |
| EBITDA Margin | -164% | XXX | -941% | XXX | XXX | XXX |
| EBIT | -$4.3M | XXX | -$5.9M | XXX | XXX | XXX |
| EBIT Margin | -177% | XXX | -1023% | XXX | XXX | XXX |
| Net Profit | -$4.3M | XXX | -$4.1M | XXX | XXX | XXX |
| Net Margin | -177% | XXX | -715% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Proteomics International's stock price is AUD 0 (or $0).
Proteomics International has current market cap of AUD 60.3M (or $38.7M), and EV of AUD 55.2M (or $35.5M).
See Proteomics International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.5M | $38.7M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Proteomics International has market cap of $38.7M and EV of $35.5M.
Proteomics International's trades at 23.5x EV/Revenue multiple, and -7.6x EV/EBITDA.
Equity research analysts estimate Proteomics International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Proteomics International has a P/E ratio of -9.0x.
See valuation multiples for Proteomics International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38.7M | XXX | $38.7M | XXX | XXX | XXX |
| EV (current) | $35.5M | XXX | $35.5M | XXX | XXX | XXX |
| EV/Revenue | 14.6x | XXX | 23.5x | XXX | XXX | XXX |
| EV/EBITDA | -8.9x | XXX | -7.6x | XXX | XXX | XXX |
| EV/EBIT | -8.2x | XXX | -7.0x | XXX | XXX | XXX |
| EV/Gross Profit | 14.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.0x | XXX | -9.2x | XXX | XXX | XXX |
| EV/FCF | -9.0x | XXX | -9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProteomics International's last 12 month revenue growth is 39%
Proteomics International's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Proteomics International's rule of 40 is -989% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Proteomics International's rule of X is -65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Proteomics International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -164% | XXX | -311% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -989% | XXX | -272% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1123% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Proteomics International acquired XXX companies to date.
Last acquisition by Proteomics International was XXXXXXXX, XXXXX XXXXX XXXXXX . Proteomics International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Proteomics International founded? | Proteomics International was founded in 2014. |
| Where is Proteomics International headquartered? | Proteomics International is headquartered in Australia. |
| Is Proteomics International publicy listed? | Yes, Proteomics International is a public company listed on ASX. |
| What is the stock symbol of Proteomics International? | Proteomics International trades under PIQ ticker. |
| When did Proteomics International go public? | Proteomics International went public in 2015. |
| Who are competitors of Proteomics International? | Similar companies to Proteomics International include e.g. Zomedica, AnteoTech, Biohit, Genomictree. |
| What is the current market cap of Proteomics International? | Proteomics International's current market cap is $38.7M |
| What is the current revenue of Proteomics International? | Proteomics International's last 12 months revenue is $2.4M. |
| What is the current revenue growth of Proteomics International? | Proteomics International revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of Proteomics International? | Current revenue multiple of Proteomics International is 14.6x. |
| Is Proteomics International profitable? | Yes, Proteomics International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Proteomics International? | Proteomics International's last 12 months EBITDA is -$4.0M. |
| What is Proteomics International's EBITDA margin? | Proteomics International's last 12 months EBITDA margin is -164%. |
| What is the current EV/EBITDA multiple of Proteomics International? | Current EBITDA multiple of Proteomics International is -8.9x. |
| What is the current FCF of Proteomics International? | Proteomics International's last 12 months FCF is -$3.9M. |
| What is Proteomics International's FCF margin? | Proteomics International's last 12 months FCF margin is -162%. |
| What is the current EV/FCF multiple of Proteomics International? | Current FCF multiple of Proteomics International is -9.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
